Acrivon Therapeutics Inc
ACRV1.280USD
+0.020+1.59%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
40.13MCap. mercado
PérdidaP/E TTM
Más Datos de Acrivon Therapeutics Inc Compañía
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. The Company uses its precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a potentially registrational Phase 2 trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore substantially improve the clinical overall response rate (ORR) and has the potential to enable expedited drug development. Its preclinical program, ACR-2316, is advancing in IND-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
Información de la empresa
Símbolo de cotizaciónACRV
Nombre de la empresaAcrivon Therapeutics Inc
Fecha de salida a bolsaNov 15, 2022
Director ejecutivoDr. Peter Blume-Jensen, M.D., Ph.D.
Número de empleados75
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 15
Dirección480 Arsenal Way, Suite 100
CiudadWATERTOWN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02472
Teléfono16172078979
Sitio Webhttps://acrivon.com/
Símbolo de cotizaciónACRV
Fecha de salida a bolsaNov 15, 2022
Director ejecutivoDr. Peter Blume-Jensen, M.D., Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peter Blume-Jensen, M.D., Ph.D.
Dr. Peter Blume-Jensen, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.21M
-3.49%
Dr. Kristina Masson, Ph.D.
Dr. Kristina Masson, Ph.D.
Executive Vice President - Business Operations, Director
Executive Vice President - Business Operations, Director
316.18K
-0.34%
Dr. Eric Devroe, Ph.D.
Dr. Eric Devroe, Ph.D.
Chief Operating Officer
Chief Operating Officer
66.53K
-0.91%
Dr. Erick Gamelin, M.D., Ph.D.
Dr. Erick Gamelin, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
16.09K
-2.44%
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mrs. Mary-Alice Miller, J.D.
Mrs. Mary-Alice Miller, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Derek Dirocco, Ph.D.
Dr. Derek Dirocco, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
--
-100.00%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peter Blume-Jensen, M.D., Ph.D.
Dr. Peter Blume-Jensen, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.21M
-3.49%
Dr. Kristina Masson, Ph.D.
Dr. Kristina Masson, Ph.D.
Executive Vice President - Business Operations, Director
Executive Vice President - Business Operations, Director
316.18K
-0.34%
Dr. Eric Devroe, Ph.D.
Dr. Eric Devroe, Ph.D.
Chief Operating Officer
Chief Operating Officer
66.53K
-0.91%
Dr. Erick Gamelin, M.D., Ph.D.
Dr. Erick Gamelin, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
16.09K
-2.44%
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
--
-100.00%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 1 de ago
Actualizado: vie., 1 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
RA Capital Management, LP
26.60%
Chione, Ltd.
12.27%
Blume-Jensen (Peter)
7.04%
Sands Capital Ventures LLC
6.77%
Citadel Advisors LLC
6.05%
Other
41.28%
Accionistas
Accionistas
Proporción
RA Capital Management, LP
26.60%
Chione, Ltd.
12.27%
Blume-Jensen (Peter)
7.04%
Sands Capital Ventures LLC
6.77%
Citadel Advisors LLC
6.05%
Other
41.28%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
26.60%
Hedge Fund
13.15%
Corporation
12.27%
Individual Investor
8.56%
Investment Advisor
7.97%
Investment Advisor/Hedge Fund
6.91%
Research Firm
0.36%
Bank and Trust
0.04%
Pension Fund
0.01%
Other
24.12%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
142
23.71M
75.61%
-5.03M
2025Q1
146
29.35M
93.70%
-2.39M
2024Q4
141
30.19M
96.96%
-1.30M
2024Q3
129
30.21M
97.90%
-1.16M
2024Q2
124
30.86M
100.26%
+1.75M
2024Q1
110
20.99M
93.28%
+95.57K
2023Q4
96
21.08M
95.04%
+130.06K
2023Q3
91
21.13M
95.90%
+687.39K
2023Q2
85
20.62M
94.10%
+177.16K
2023Q1
71
22.16M
102.70%
+6.28M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
RA Capital Management, LP
8.34M
26.6%
--
--
Mar 31, 2025
Chione, Ltd.
3.85M
12.27%
--
--
Jun 30, 2024
Blume-Jensen (Peter)
2.21M
7.04%
-79.67K
-3.49%
May 21, 2025
Sands Capital Ventures LLC
2.12M
6.77%
--
--
Mar 31, 2025
Citadel Advisors LLC
1.90M
6.05%
-224.13K
-10.57%
Mar 31, 2025
Wellington Management Company, LLP
888.13K
2.83%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
844.91K
2.69%
-5.84K
-0.69%
Mar 31, 2025
The Vanguard Group, Inc.
674.79K
2.15%
+3.17K
+0.47%
Mar 31, 2025
Marshall Wace LLP
450.39K
1.44%
-147.40K
-24.66%
Mar 31, 2025
Acorn Capital Advisors, LLC
405.24K
1.29%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Value ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
iShares Russell 2000 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Biotechnology ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Ver más
iShares Micro-Cap ETF
Proporción0.01%
iShares Russell 2000 Value ETF
Proporción0%
Invesco Nasdaq Biotechnology ETF
Proporción0%
ProShares Ultra Nasdaq Biotechnology
Proporción0%
iShares Russell 2000 ETF
Proporción0%
DFA Dimensional US Sustainability Core 1 ETF
Proporción0%
iShares Biotechnology ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
Global X Russell 2000 ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
